News

APP Pharma and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex, which is currently

TZP-102 is an oral ghrelin agonist with potent prokinetic properties currently in clinical development for the treatment of chronic gastrointestinal dysmotility disorders such as gastroparesis, functional dyspepsia, and

The expansion will take place in the third quarter of 2011 and is expected to be completed in the second quarter of 2012. Lanxess said that the new

Aestus is expected to develop the product as ATx08-001, a novel therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year. Aestus

Suzhou Erye pharma said that its new facility now has obtained government certification, is now fully operational and is manufacturing products on these two production lines. The new

Abbott had received independent 510(k) clearances for both the Abbott RealTime Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) assay and the Abbott m2000 System. They are required to be used together

OrSense said that the presentation provides data of NBM 200, a non-invasive Hb measurement system for various hematological applications including anemia monitoring, hemorrhage detection and pre-donation screening. Hb

As per the terms of the agreement MMV is expected to initially have access to AstraZeneca’s compound library. MMV is also expected to seek to identify compounds that

Forest Labs and Gedeon Richter have evaluated the investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, Radiprodil (RGH-896) in the clinical trial for the treatment of neuropathic pain associated